Intellia reports Phase 3 trial shows lonvo-z cuts hereditary angioedema attacks 87% vs placebo

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

NTLA

0.00
  • Intellia presented additional Phase 3 HAELO results for lonvo-z in hereditary angioedema at EAACI 2026; the study was published in NEJM.
  • The one-time CRISPR treatment cut attack burden versus placebo, leaving many patients attack-free without ongoing preventive therapy during the evaluation period.
  • Quality-of-life outcomes improved versus placebo; safety looked manageable with mostly mild-to-moderate side effects and no serious events in the treatment arm.
  • A rolling BLA started in April; U.S. approval and launch remain targeted for H1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606130730PRIMZONEFULLFEED9746404) on June 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.